ArticleBMC neurology2026
Biomarkers for satralizumab treatment in neuromyelitis optica spectrum disorders: a prospective case series.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSatralizumab reduces relapse risk in neuromyelitis optica spectrum disorder (NMOSD). However, dynamic biomarker changes during treatment have not been systematically characterized. We conducted this prospective self-controlled case series to evaluate longitudinal changes in multiple biomarkers during satralizumab treatment and identify potential indicators of disease activity and therapeutic response.
methodsWe enrolled four AQP4-IgG-positive NMOSD patients receiving satralizumab for 24 months with serial blood sampling at 13 timepoints (baseline and months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, and 24). Clinical outcomes and candidate biomarkers (serum AQP4-IgG, glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL], chitinase-3-like protein 1 [CHI3L1], triggering receptor expressed on myeloid cells 2 [TREM2], IL-6, IL-6Rα, CD19+CD27+CD38+ B-cell ratio, and Treg-cell ratio) were analyzed.
resultsIn the four patients, patient 3 (P3) experienced two relapses at months 1 and 7 after satralizumab treatment initiation; the remaining three patients remained relapse-free. Expanded Disability Status Scale scores in all patients were stable or improved at final follow-up. Serum AQP4-IgG, GFAP, and NfL showed trajectories parallel to satralizumab response and disease activity. CHI3L1 reflected therapeutic effects but was less sensitive than GFAP or NfL. TREM2, IL-6, and IL-6Rα showed no prominent changes. Satralizumab reduced CD19+CD27+CD38+ plasmablasts and increased Treg-cell proportion in some patients.
conclusionSerum AQP4-IgG, GFAP, and NfL may be promising biomarkers of NMOSD disease activity and satralizumab treatment response. Further well-designed multicenter large-scale clinical studies are needed to validate the clinical utility of these biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.